KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)

被引：13
|
作者：
Nanda, R.
Specht, J.
Dees, C.
Berger, R.
Gupta, S.
Geva, R.
Pusztai, L.
Pathiraja, K.
Ray, A.
Karantza, V.
Buisseret, L.
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Univ North Carolina Lineberger Comprehens Canc Ct, Chapel Hill, NC USA
[4] Sheba Med Ctr, Tel Hashomer, Israel
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[7] Yale Univ Sch Med, New Haven, CT 06520 USA
[8] Merck & Co Inc, Kenilworth, NJ USA
[9] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-10-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-10-03
引用
收藏
页数：2
相关论文
共 50 条
  • [21] KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1-positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)
    Adams, Sylvia
    Loi, Sherene
    Toppmeyer, Deborah L.
    Cescon, David W.
    De laurentiis, Michele
    Nanda, Rita
    Winer, Eric P.
    Mukai, Hirofumai
    Tamura, Kenji
    Armstrong, Anne C.
    Liu, Minetta C.
    Iwata, Hiroji
    Ryvo, Larisa
    Wimberger, Pauline
    Rugo, Hope S.
    Tan, Antoinette
    D'Aquanno, Christine
    Ding, Yu
    Karantza, Vassiliki
    Schmid, Peter
    CANCER RESEARCH, 2018, 78 (04)
  • [22] Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation
    Im, S-A.
    Cortes, J.
    Lipatov, O.
    Goncalves, A.
    Lee, K-S.
    Schmid, P.
    Tamura, K.
    Testa, L.
    Witzel, I.
    Ohtani, S.
    Zambelli, S.
    Harbeck, N.
    Andre, F.
    Dent, R.
    Lin, J.
    Karantza, V.
    Mejia, J. A.
    Winer, E. P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1258 - S1258
  • [23] A phase II study of cisplatin and the Wee1 inhibitor adavosertib in metastatic triple-negative breast cancer (mTNBC)
    Keenan, Tanya E.
    Tan-Wasielewski, Zhenying
    Trippa, Lorenzo
    Kochupurakkal, Bose
    Guerriero, Jennifer L.
    Tahara, Rie K.
    Winship, Grace
    Osmani, Wafa
    Andrews, Chelsea
    Conway, Jake R.
    He, Meng X.
    Pastorello, Ricardo
    Tracy, Adam
    Godin, Robert E.
    Overmoyer, Beth A.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Shapiro, Geoffrey I.
    Van Allen, Eliezer M.
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [24] Long-Lasting Control of Triple-Negative Metastatic Breast Cancer with the Novel Drug Combination Ixabepilone and Capecitabine - Case Report
    Vrdoljak, Eduard
    Mise, Branka Petric
    Lukic, Blanka
    Curic, Zvonimir
    Boskovic, Lidija
    Tica, Ivana
    ONKOLOGIE, 2010, 33 (1-2): : 53 - 56
  • [25] Phase 1b/2 Study to Evaluate Eribulin Mesylate (ERI) in Combination with Pembrolizumab (PEM) in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
    Tolaney, Sara
    Savulsky, Claudio
    Aktan, Gursel
    Xing, Dongyuan
    Almonte, Ana
    Karantza, Vasiliki
    Janevski, Mile
    Diab, Sami
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 122 - 122
  • [26] Results of a phase II study of capecitabine-based doublets in the treatment of metastatic triple-negative breast cancer (mTNBC)
    Fan, Ying
    Xu, Binghe
    Liao, Yuqian
    Ma, Fei
    Yuan, Peng
    Wang, Jiayu
    Zhang, Pin
    Li, Qing
    Xuan, Lixue
    Luo, Yang
    Ding, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] An open label, multicenter phase II study combining imprime PGG (PGG) with pembrolizumab (P) in previously treated metastatic triple-negative breast cancer (mTNBC).
    O'Day, Steven
    Borges, Virginia F.
    Chmielowski, Bartosz
    Rao, Ruta D.
    Abu-Khalaf, Maysa M.
    Stopeck, Alison
    Nikolinakos, Petros
    Telli, Melinda L.
    Xie, Bin
    Shaheen, Montaser F.
    Mattson, Paulette
    Gargano, Michele Anne
    Cox, Joanna
    Karantza, Vassiliki
    Chisamore, Michael Jon
    Osterwalder, Bruno
    Bose, Nandita
    Uhlik, Mark T.
    Graff, Jeremy
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086
    Loi, S.
    Adams, S.
    Schmid, P.
    Cortes, J.
    Cescon, D. W.
    Winer, E. P.
    Toppmeyer, D. L.
    Rugo, H. S.
    De laurentiis, M.
    Nanda, R.
    Iwata, H.
    Awada, A.
    Tan, A.
    Wang, A.
    Aktan, G.
    Karantza, V.
    Salgado, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)
    Loi, Sherene
    Winer, Eric
    Lipatov, Oleg
    Im, Seock-Ah
    Goncalves, Anthony
    Cortes, Javier
    Lee, Keun S.
    Schmid, Peter
    Testa, Laura
    Witzel, Isabell
    Ohtani, Shoichiro
    Turner, Nicholas
    Zambelli, Stefania
    Harbeck, Nadia
    Andre, Fabrice
    Dent, Rebecca
    Huang, LingKang
    Mejia, Jaime
    Karantza, Vassiliki
    Salgado, Roberto
    CANCER RESEARCH, 2020, 80 (04)
  • [30] TREATMENT PATTERNS OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC) IN US COMMERCIAL PLANS
    Jiang, S.
    Hill, K.
    Varghese, D.
    Waldeck, R.
    Botteman, M.
    VALUE IN HEALTH, 2017, 20 (05) : A127 - A127
12345